Drug Week articles from October 2002

Drug Week archives from October 2002

Duke researchers develop method to make safer drugs.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Using blood thinners as a model, researchers at Duke University Medical Center believe they have found a way to safely turn on and off the effects of drugs, or in this case, reverse the blood-thinning...

Frovatriptan highly effective in preventing menstrual migraine.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Vernalis Group plc (VER) has announced the successful outcome of a large multicenter study that demonstrated the significant benefits of using frovatriptan, its newly marketed antimigraine treatment, in...

Medinol completes patient enrollment in NIRflex U.S. clinical trial.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Medinol, Ltd., a leader in stent technology, has completed patient enrollment in its NIRflex U.S. clinical trial to collect information about the safety and efficacy of a next generation premounted...

National coverage decision to be issued for the use of levocarnitine.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- The Centers for Medicare and Medicaid Services (CMS) has announced its intent to issue a national coverage determination for intravenous levocarnitine, a pharmaceutical treatment for carnitine...

U.N. health agency publishes first-ever global reference guide for essential medicines.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- In a bid to promote the safe and cost-effective use of medicines, the World Health Organization (WHO) has released a guide to help governments develop their own national prescription formulas. The...

Genetic revolution revealing role for sex-specific medicines.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Women with narcolepsy respond differently than men to treatment with the drug modafinil. This difference may be due to a sex-specific variation in one gene, according to results of a recent study. ...

Phase II trial for VitrenASE initiated.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Immusol, The Inverse Genomics Co., announced that it has initiated a phase II clinical trial for its lead product, VitrenASE, for proliferative vitreoretinopathy (PVR), a serious eye disease...

Onco TCS clinical program expanded.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Inex Pharmaceuticals Corporation (INEX; IEX) announced that it has expanded the clinical development program for its lead anticancer product Onco TCS to include a new phase I/II human clinical trial...

Positive results announced in phase II clinical trial of INS37217.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Inspire Pharmaceuticals, Inc., (ISPH) announced that results of a phase II clinical trial for INS37217 Intranasal in patients with perennial allergic rhinitis (PAR). INS37217 demonstrated...

Collaboration expanded for target characterization, drug discovery.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Cambridge Antibody Technology (CATG; CAT) and Xerion Pharmaceuticals AG announced the expansion of their existing business relationship into a research collaboration for target characterization and drug...

Introduction of generic Claritin will reduce antihistamine market.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced that the introduction of generic forms of Claritin...

Neurobiological receives $1.4 million from Merz for Memantine European launch.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Neurobiological Technologies, Inc., (NTII) announced that it has received a $1.4 million payment from Merz Pharmaceuticals GmbH (Merz) for achieving goals related to the marketing launch of Memantine in...

Milestone achieved in drug discovery collaboration.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc., (ISIS) announced that it has achieved a research milestone in its drug discovery collaboration with Amgen (AMGN). Isis has received a payment from Amgen for the...

Paradigm Genetics announces executive management changes.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Paradigm Genetics, Inc., (PDGM), a life-sciences company, announced the appointment of Thomas Colatsky, PhD, to the position of vice president, healthcare research. Colatsky brings more than 20...

Phytomedics and Rutgers extend R&D agreement.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Phytomedics, Inc., a private biopharmaceutical company discovering and developing botanical therapeutics, announced the signing of a 5-year $4.3 million research and licensing agreement to continue its...

Innovative i.v. drug to treat severe burns in children starts phase II.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Each year, thousands of children suffer burn-related accidents, often with long-lasting consequences and disfigurement. Burn injuries constitute one of the greatest hazards of childhood, and...

Sicor announces tentative ANDA approval for carboplatin injection.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Sicor Inc., (SCRI) announced that the Food and Drug Administration (FDA) has tentatively approved an abbreviated new drug application (ANDA) by its wholly owned subsidiary, Gensia Sicor Pharmaceuticals,...

Clinical trial of VT-111, anti-inflammatory protein, begins.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Viron Therapeutics, Inc., announced the initiation of "first-in-man" studies with its lead product, VT-111. The double-blind placebo-controlled phase I clinical trial is being conducted in...

New antidepressant awaited, but little proof it's much better.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- U.S. psychiatrists can now prescribe an eagerly awaited new antidepressant called Lexapro. It's being promoted as more potent and possibly safer than older competitors - but there's little evidence that...

FDA approves Lexapro for depression.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Forest Laboratories, Inc., (FRX) announced that Lexapro (escitalopram oxalate), a powerful, effective, and well-tolerated selective serotonin reuptake inhibitor (SSRI), has been approved by the U.S....

Company granted controlled drugs, substances license.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced that it has been granted a Controlled Drugs & Substances License by Health Canada. The license...

MorphoSys announces first milestone in Centocor antibody collaboration.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- MorphoSys AG (MOR), the Munich-based biotechnology company, announced the achievement of a first milestone in its therapeutic antibody cooperation with Centocor, Inc. MorphoSys receives an...

Type 2 diabetic patients can manage dyslipidemia with daily niacin treatment.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Daily therapy with an extended-release form of niacin can successfully control dyslipidemia in patients with type 2 diabetes, according to researchers...

MacroChem completes tolerance trials of topical ED drug.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- MacroChem Corp. (MCHM) announced that it has successfully completed preclinical efficacy and clinical tolerance studies of new formulations of its investigational topical treatment for erectile...

Genomics-based drug discovery company shows 2Q 2002 net loss: $0.36 per share.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Genome Therapeutics Corp. (GENE) released financial results for the second quarter ended June 29, 2002. In line with prior guidance, the company reported a net loss for the quarter of $8,317,000,...

Increased licensing revenues improve operating results for antibody-based technology company.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., (IMMU) reported revenues of $4.3 million and a net loss of $1.8 million, or $0.04 per share, for the fourth quarter of its fiscal year ended June 30, 2002, excluding a one-time...

Second quarter 2002 net loss reported by developer of medicines from genomics, natural products.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Genaera Corporation (GENR) announced its financial results for the 3 and 6 months ended June 30, 2002. The net loss applicable to common shareholders for the 3 months ended June 30, 2002, was...

Third quarter yields net loss of $0.26 per share for company focusing on tissue damage.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Incara Pharmaceuticals Corporation (INCR) announced the financial results for its third quarter of fiscal 2002, the 3-month period ended June 30, 2002. The company also included recent progress...

Amprenavir prodrug can reduce pill burden.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United Kingdom may have found a way to reduce HIV patients' pill burden during some antiretroviral drug regimens. C. Falcoz and...

Caveolin-1 can prevent viral protein expression.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have identified a protein that could act as a novel treatment for HIV infection. "Caveolin-1 (Cav-1) is a major protein...

Persistent TMC-126 efficacy in face of resistance mutations elucidated.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have shed new light on the mechanisms of a powerful second-generation inhibitor of HIV protease. "Biochemical and clinical...

FDA approves blood pressure treatment for additional indication.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- The U.S. Food & Drug Administration (FDA) approved a leading high blood pressure medicine Diovan (valsartan) to treat heart failure in patients who are intolerant of angiotensin-converting-enzyme (ACE)...

Positive results of long-term safety, toxicology study of Oralin reported.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced continued positive results from its long-term (two years) safety and toxicology study of Oralin, the...

Court of Appeals victory for generic version of Depakote.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Apotex Corp. announced that the Court of Appeals for the Federal Circuit reversed a summary judgment that the U.S. District Court for the Northern District of Illinois granted last year in Abbott's suit...

Judge rules OxyContin lawsuit can be class action.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- A lawsuit that accuses the makers of OxyContin of irresponsibly marketing the powerful painkiller to Ohioans has been certified as a class action. "The abuse, intentional or accidental, of...

West Virginia judge dismisses OxyContin case against Purdue Pharma.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- A state court judge has dismissed the claims of a West Virginia plaintiff against Purdue Pharma, L.P., the Stamford, Connecticut-based distributor of OxyContin (oxycodone HCl controlled-release)...

Clofarex web site launched.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Ilex Oncology, Inc., (ILXO) announced the launch of www.clofarex.com. Clofarex (clofarabine), a second-generation nucleoside analogue, is currently being studied as a potential treatment for...

NeoPharm initiates new global trial of IL13-PE38.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- NeoPharm, Inc., (NEOL) announced further progress in its clinical development program for IL13-PE38, NeoPharm's tumor-targeted agent. Enrollment has begun in the first global phase I/II clinical...

Pharmaceutical blockbusters can be built in a crowded market.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Top performing product launches demonstrate operational excellence in the critical management areas of product development, organizational development, and market development. Leading...

NY DEA investigation leads to $2 million fine against Advance Pharmaceutical.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- As the result of a lengthy investigation by the New York Drug Enforcement Administration's Long Island District Office into the activities of Advance Pharmaceutical Inc., of Ronkonkoma New York, a civil...

VCU discovery shows that Viagra protects the heart.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- A researcher at Virginia Commonwealth University has invented a new and potentially important use for the male impotence drug, Viagra - heart protection. The discovery by Dr. Rakesh C. Kukreja,...

Metabolic Pharmaceuticals sees positive results from weight-loss drug.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Metabolic Pharmaceuticals reported the successful completion of its phase IIA human clinical trial of obesity drug AOD9604 by single-dose oral administration, showing positive results. "This...

Obese adolescents benefit from orlistat therapy.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Morbidly obese adolescents who underwent short-term orlistat treatment lost weight and experienced improvements in lipid profiles and insulin...

NPS reports interim Preos carcinogenicity results.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) reported interim results from an ongoing 24-month preclinical carcinogenicity study with Preos, its proprietary drug candidate for treating osteoporosis. A planned...

Xyotax to be tested in recurrent, chemotherapy-resistant cancer.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Cell Therapeutics, Inc., (CTI) (CTIC) announced that the Gynecologic Oncology Group (GOG), a cooperative of many of the most prominent physicians and institutions in the United States, has activated a...

FDA approval granted for meperidine hydrochloride.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- Caraco Pharmaceutical Laboratories, Ltd., (CARA) has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market meperidine hydrochloride, a generic form of Sanofi-...

Progress in pneumococcal vaccine development reported.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A need exists for inexpensive pneumococcal vaccines that cover a broad serotype range, according to a review in the Scandinavian Journal of...

Jehovah's Witness gets synthetic blood.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- A 38-year-old Colorado Springs, Colorado woman has received a rare emergency transfusion of experimental synthetic blood at Denver Health Medical Center. As a Jehovah's Witness, Sheryl Padilla was...

Pulmonary lesions after treatment initiation usually transient.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - New pulmonary lesions developing after the initiation of antituberculosis therapy are not generally indicative of problems with treatment, researchers in South...

Pyrazinamide, levofloxacin interact poorly.
October 4, 2002... 2002 OCT 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Patients suffering from multidrug-resistant tuberculosis should not be treated with both pyrazinamide and levofloxacin, researchers in Canada report. "The...

Interleukin-2 safe for patients with low HHV-8 viremia.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Supplemental interleukin-2 treatment is safe for most HIV patients coinfected with the virus responsible for Kaposi sarcoma, researchers in Italy say. ...

Raloxifene increases level of protein believed to inhibit estrogen-sensitive breast cancer.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- In a study supported by Eli Lilly and Co. and published in the September 2002 issue of Fertility and Sterility, researchers at Boston's Beth Israel Deaconess Medical Center, the Medical Center for...

Former insider lashes out at FDA's links with pharmaceutical industry.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- A former senior consultant with the U.S. Food and Drug Administration (FDA) has criticized the American regulator's close relationship with the pharmaceutical industry. Interviewed in the British...

New study combines Prograf with Rapamune or CellCept.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Results of a clinical study combining Prograf (tacrolimus)-based immunosuppression with Rapamune (sirolimus) or CellCept (mycophenolate mofetil) were presented at the XIX International Congress of the...

Cerivastatin benefits type 2 diabetic patients.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Obese patients with type 2 diabetes experienced improvements in insulin sensitivity and insulin secretion while taking cerivastatin, according to...

Metformin combined with glibenclamide safe and effective for control of type 2 diabetes.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Researchers in France found that combined metformin-glibenclamide therapy for type 2 diabetes offered better glycemic control than either medication...

Trinity announces Remune study results.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Trinity Medical Group USA, Inc., (GU) publicly announced clinical results presented at a scientific conference on therapeutic and preventive HIV vaccines indicating that HIV-positive patients in...

Board recommends to breaking code of Coviracil pivotal trial early.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Triangle Pharmaceuticals, Inc., (VIRS) announced positive findings from FTC-301, an ongoing pivotal phase III trial of Coviracil (emtricitabine), its nucleoside reverse transcriptase inhibitor for the...

Neurochem files IND application for Alzhemed.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Neurochem, Inc., (NRM) announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for Alzhemed, the company's lead candidate for the treatment...

FDA approves Kytril for prevention, treatment of postop nausea, vomiting.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Roche announced that the U.S. Food and Drug Administration (FDA) granted approval of its antiemetic, Kytril Injection (granisetron hydrochloride) for both the prevention and treatment of postoperative...

Single-step technology enables synthesis of cyclosporin.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Enanta Pharmaceuticals, Inc., presented its proprietary single-step chemistry technology that enables synthesis of novel cyclosporin A softdrug analogs as potential asthma therapeutics. The...

Ranbaxy gains FDA approval to market terazosin hydrochloride capsules.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Ranbaxy Pharmaceuticals, Inc., (RPI), a wholly owned subsidiary of Ranbaxy Laboratories, Ltd., (RLL), announced that RLL has received final approval from the U.S. Food and Drug Administration to...

Biotech company prepares to launch therapy for refractory breast cancer in the U.K.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Biotechnology company Bioenvision is set to launch a major new weapon in the fight against breast cancer. Modrenal is a refractory breast cancer treatment, which will be used in cases where front...

Genentech stock plummets after drug fails key test.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Shares of Genentech, Inc. plummeted after an announcement that a once-promising experimental breast cancer drug had failed a clinical trial. The South San Francisco-based company announced...

FDA grants priority review for Gleevec.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Novartis Oncology announced that Gleevec (imatinib mesylate) has been granted priority review by the U.S. Food and Drug Administration (FDA) for possible use as a first-line treatment for newly...

Eloxatin distribution begun.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Sanofi-Synthelabo (SNY) announced that it began distribution of Eloxatin (oxaliplatin for injection), a new chemotherapy drug for metastatic colorectal cancer, to oncologists' offices throughout the...

Aminoguanidine helps prevent kidney damage in diabetic baboons.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A study done in baboons by investigators in Australia demonstrated aminoguanidine (AG) offered some protection against diabetic nephropathy. ...

Response submitted to NICE on Lantus.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- The National Institute for Clinical Excellence (NICE) has published its Appraisal Consultation Document (ACD) - a preliminary determination - on the use of Lantus (insulin glargine) - a newly available...

AARP members urge Senate to help lower drug costs.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- AARP Pennsylvania has received 15,000 calls and letters within the past year from families throughout Pennsylvania who are on fixed incomes and are faced with the gruesome task of having to cut basic...

Snake venom antibodies produced in chicken egg yolk.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Researchers in India have developed a simple way to produce antivenom immunoglobulins in chicken egg yolk. They published their report in the journal Toxicon. "The therapeutic use of specific...

Changes in fetal tissue gene expression predict drug estrogenicity.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- According to recent research from the United States, "Exposure to some compounds with estrogenic activity, during fetal development, has been shown to alter development of reproductive organs, leading...

Filgrastim may interfere with antiretroviral efficacy.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States say that a hematopoietic growth factor used to supplement HIV treatment may actually hinder antiviral suppression. ...

Once-daily quadruple regimen safe, effective.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A once-daily regimen combining four antiretroviral agents in safe and effective, researchers in the United States report. Gail Skowron and colleagues at...

Product R clinical trial results subject of published study.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that the results of a randomized, controlled, and blinded clinical study of Product R therapy in patients with HIV/AIDS have been published in the journal...

Study may help Nebraska heart patient grow blood vessels.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Surgeons grafted new blood vessels onto the oxygen-starved heart of Jack Wilbur a few years ago, bypassing four blocked arteries. Now, two of those vessels deliver insufficient amounts of blood,...

Sankyo submits sNDA for new combination Benicar HCT.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Sankyo Pharma, Inc., has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) for its combination therapy drug, Benicar HCT (olmesartan...

Patents protecting Niaspan challenged.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) announced that it has been sued by Kos Pharmaceuticals, Inc., (KOSP), which initiates Barr's challenge of the patents protecting Kos' Niaspan 500 and 750 mg...

Clinical trial initiated for Squalamine.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Genaera Corporation (GENR) announced commencement of a phase I-II clinical trial designed to test squalamine, an angiogenesis inhibitor, for the treatment of the "wet" (choroidal neovascularization)...

FDA approves new safety data for Malarone.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration approved the addition of new safety data to the prescribing information of GlaxoSmithKline's Malarone (atovaquone and proguanil hydrochloride) Tablets,...

Enrollment of additional patients delayed in trial for Chronogesic.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Durect Corporation (DRRX) announced that, following discussions between Durect and the FDA on Durect's on-going phase III clinical trial for the Chronogesic (sufentanil) Pain Therapy System, the FDA...

FDA to consolidate review responsibilities for new pharmaceutical products.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- Dr. Lester M. Crawford, deputy commissioner of the U.S. Food and Drug Administration (FDA), has announced the consolidation of FDA's responsibility for reviewing new pharmaceutical products into its...

Ursodeoxycholic acid can prevent post-transplant liver dysfunction.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Ursodeoxycholic acid (UDCA) can help prevent liver disorders often seen after allogeneic stem cell transplantation, researchers report. Tapani Ruutu and...

Transplants in HIV patients should proceed, but drug interactions a concern.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- While historically surgeons have been reluctant to transplant patients with the human immunodeficiency virus (HIV), in recent years some centers have begun to accept patients with well-controlled HIV...

Bupropion aids sustainable loss of weight.
October 11, 2002... 2002 OCT 11 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Obese adults who took bupropion lost a significant amount of weight and maintained the weight loss for almost a year. James W. Anderson, at the...